A Phase II Preventative Trial of DFMO as a Single Agent in Patients With High Risk Neuroblastoma in Remission
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 May 2017
At a glance
- Drugs Eflornithine (Primary)
- Indications Neuroblastoma
- Focus Therapeutic Use
- 10 May 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jun 2018.
- 10 May 2016 Status changed from recruiting to active, no longer recruiting.
- 09 Nov 2015 Status changed from active, no longer recruiting to recruiting, as reported by ClinicalTrials.gov.